



6 February 2007

For Immediate Release

LumaCare® receives an EPO Patent for the LC-122 family of non Coherent Light Sources used in PDT and Phototherapeutic Applications

Newport Beach, CA

The European Patent Office (EPO) has granted LumaCare Medical Group a patent (EP 1124613 B1) on their LumaCare® Model LC122 Non Coherent Light Source and their revolutionary Fiber Optic Probes (FOP) delivery system. In addition to the existing USPTO Patent grants, LumaCare now has a worldwide patent position on their non-coherent Light Source.

The recent Food and Drug Administration (FDA) approval and issuance of a Premarket Notification (510K) for LumaCare® LC122M Phototherapeutic Light Source completes all regulatory requirements for selling directly to any End-User worldwide.

This expanded IP position coupled with CE-MDD and FDA Approvals, provides LumaCare Users the most protocol flexible light source available for PDT or Phototherapeutic requirements.

LumaCare® is the leading provider of non-coherent Light Sources for Phototherapeutic Applications as well as Photodynamic Therapy (PDT). PDT is a safe and effective treatment for the most common forms of skin cancer and pre-malignant lesions. According to newly issued clinical reports at the EADV 2006 Congress in Rhodes, Greece, Photodynamic Therapy is as safe and effective as cryosurgery and produces significantly better cosmetic results.

LumaCare offers the patented LC-122M as a safe, effective, simple, and low cost solution to expensive lasers and LED arrays costing at a minimum more than \$25,000. LumaCare's LC122M End-User price is only \$7,500 compared to lasers and LED starting at \$25,000.

LumaCare LC-122M is FDA and CE-MDD approved and is routinely used throughout Europe, the Americas and the Pacific Rim Countries. LumaCare is recommended for Phototherapeutic applications as well as PDT, treating basal cell carcinoma and pre-malignant lesions such as actinic (solar) keratoses and Bowen's disease. Basal cell carcinoma, the most common skin cancer, when not treated properly can cause extensive tissue destruction. Actinic or solar Keratoses, hard lumps in the skin from the effects of sun damage, are usually harmless but can potentially develop into squamous cell carcinoma. It is impossible to predict which of the very common Solar keratoses lesions will develop into cancer.

LumaCare® light sources are designed especially for Phototherapeutic treatments such as Acne and almost all PDT protocols. LumaCare is marketed in the USA by The LumaCare Medical Group a division of MBG Technologies Inc.

LumaCare® light sources have the patented unique functionality to meet the activation requirements of all Phototherapeutic applications and PDT drugs.

LumaCare® is the one source solution for any Phototherapy application or PDT drug activation. LumaCare® is the leading provider of Phototherapeutic and PDT flexible multi-frequency lights sources.

Only LumaCare with its patent protocol flexible interchangeable Fiber Optic Probes (FOP) can deliver the necessary light frequencies required for almost any Phototherapeutic application or PDT drug activation.

For further information, and contact details:

LumaCare® Medical Group is an operating unit of MBG Technologies. LumaCare's charter is to design and market simple, safe, reliable, and low cost Light Sources into the Medical market as a viable alternative to complex and capital intensive laser and LED based systems. LumaCare was founded over 10 years ago and the parent company MBG Technologies was founded in 1990.

For additional information, please visit our web sites:

Web sites: www.LumaCare.com,

e-mail: info@LumaCare.com

In the European Union, contact Dr. Jon Exley, Lynton Lasers, at phone: +44 (1477) 5369777.

In the USA, please call the Newport Beach, CA office at 1-949-644-0126.

LumaCare® is a patented medical device covered by one ore more of the following International and USPTO Patents: 5,849,027, 6.187,030, EP 1,124,613 B1.

All registered trademarks (®) are property of their respective companies/owners.